Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials

NCT00828919 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: axitinib
DRUG: crizotinib

Sponsor

Pfizer